Mohamed ElMandouh Mohamed
Ain Shams Maternity Hospital
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Mohamed ElMandouh Mohamed as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 10:56 UTC. Open this list on ClinicalTrials.gov
- Ph4NCT07465016 · Laminaria Japonicum Followed by Misoprostol Versus Misoprostol Alone for Mid-Trimester Abortion Induction in Scarred UterusPavly Maged Jimmy Fouad · completed · Induction of Abortion, Scarred Uterus · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-12 10:56 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 10:56 UTC. The ranking covers the 200 most relevant of 42 PubMed records, and a shared surname and initials can bring in a namesake. All 42 on PubMed
- Upadacitinib Induction and Maintenance Therapy for Crohn's Disease.N Engl J Med · 2023434 citationsRCR 52.7
- 371 citationsRCR 15.9
- Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial.J Allergy Clin Immunol · 2020296 citationsRCR 16.9
- Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn's Disease.Gastroenterology · 2020279 citationsRCR 13.8
- 202 citationsRCR 10.9
- Pharmacokinetics, Safety and Tolerability of ABT-494, a Novel Selective JAK 1 Inhibitor, in Healthy Volunteers and Subjects with Rheumatoid Arthritis.Clin Pharmacokinet · 2016106 citationsRCR 3.6
- Assessment of effect of CYP3A inhibition, CYP induction, OATP1B inhibition, and high-fat meal on pharmacokinetics of the JAK1 inhibitor upadacitinib.Br J Clin Pharmacol · 201760 citationsRCR 2.5
- Efficacy and Safety of Upadacitinib or Elsubrutinib Alone or in Combination for Patients With Systemic Lupus Erythematosus: A Phase 2 Randomized Controlled Trial.Arthritis Rheumatol · 202457 citationsRCR 8.7
- Pharmacokinetics of Upadacitinib With the Clinical Regimens of the Extended-Release Formulation Utilized in Rheumatoid Arthritis Phase 3 Trials.Clin Pharmacol Drug Dev · 201951 citationsRCR 2.1
- Population Pharmacokinetics of Upadacitinib Using the Immediate-Release and Extended-Release Formulations in Healthy Subjects and Subjects with Rheumatoid Arthritis: Analyses of Phase I-III Clinical Trials.Clin Pharmacokinet · 201950 citationsRCR 2.2